Demcizumab, identified as OMP 21M18 and assigned the CAS registry number 1243262-17-0, constitutes a novel monoclonal protein designed to principally blocking a effect of angiopoietin- receptor- 2. Studies demonstrate https://charliesjue696269.aboutyoublog.com/profile